---
title: "SPRINT: No revenue in Q2/H1 2026, losses widened, NNMT expanded, and cash rose to 93.3 MSEK"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296990841.md"
description: "Revenue dropped to zero in Q2 and H1 2026, widening losses despite lower costs. NNMT program expanded to chronic kidney disease, and a new AI-driven partnership with Lilly TuneLab was established. Cash position improved to 93.3 MSEK at period end.Original document: Sprint Bioscience AB [SPRINT] Interim report — Aug. 26 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-26T05:30:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296990841.md)
  - [en](https://longbridge.com/en/news/296990841.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296990841.md)
generator: "portal-rs"
---

# SPRINT: No revenue in Q2/H1 2026, losses widened, NNMT expanded, and cash rose to 93.3 MSEK

Revenue dropped to zero in Q2 and H1 2026, widening losses despite lower costs. NNMT program expanded to chronic kidney disease, and a new AI-driven partnership with Lilly TuneLab was established. Cash position improved to 93.3 MSEK at period end.

Original document: Sprint Bioscience AB \[SPRINT\] Interim report — Aug. 26 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)

## Related News & Research

- [BioArctic Q2 FY26 turns to net loss of SEK 11.2 million; revenue falls to SEK 247.5 million](https://longbridge.com/en/news/296992922.md)
- [How Eli Lilly’s Global Vault CRM Rollout At Veeva Systems (VEEV) Has Changed Its Investment Story](https://longbridge.com/en/news/296430987.md)
- [02:46 ETBioArctic: Interim Report for the period April - June 2026](https://longbridge.com/en/news/296997614.md)
- [BIOA_B: Leqembi sales and royalties surged, partnerships expanded, and cash reserves remained strong](https://longbridge.com/en/news/296995614.md)
- [Laekna Advances Obesity Drug LAE102 With Positive Phase I Data](https://longbridge.com/en/news/296933979.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**